Camlin Fine Sciences Standalone Sales Rise 16.22% in June 2026

Camlin Fine Sciences Limited reported standalone net sales of ₹222.49 crore for June 2026, up 16.22% year on year, highlighting growth in the company’s standalone business ahead of its November 3, 2026 board meeting on September-quarter and half-year results.

What did Camlin Fine Sciences report for June 2026?

Camlin Fine Sciences reported standalone net sales of ₹222.49 crore in June 2026, compared with the corresponding period a year earlier, representing year-on-year growth of 16.22%. The reported figure relates specifically to the standalone business and should not be directly compared with consolidated revenue without accounting for the different reporting scope.

The available information does not provide standalone operating profit, net profit, margin, or cash-flow data alongside the ₹222.49 crore sales figure. As a result, the sales increase establishes revenue growth but does not by itself show whether profitability moved in the same direction during the period.

Camlin Fine Sciences operates in the specialty chemicals space. For shareholders, the June standalone sales number is relevant because it gives a view of revenue generated by the parent entity, while consolidated accounts incorporate the financial performance of subsidiaries and other entities included in the group.

How do the reported figures compare across reporting scopes?

The June 2026 standalone net sales of ₹222.49 crore differ materially from the consolidated sales figures cited in the company’s quarterly data, underlining the importance of distinguishing between standalone and group-level results. The quarterly table in the supplied data lists sales of ₹520 crore for June 2026, against ₹425 crore in March 2026 and ₹408 crore in June 2025.

That table shows consolidated sales rising 22.4% sequentially from ₹425 crore in March 2026 to ₹520 crore in June 2026. It also lists operating profit of ₹9 crore for June 2026, with an operating profit margin of 1.8%, compared with ₹21 crore and a 5.0% margin in March 2026. These figures indicate that the reported increase in consolidated sales was accompanied by lower operating profit and margin in that dataset.

Another update states that revenue from operations was ₹519.88 crore and that expenses were ₹529.76 crore. Cost of materials consumed was ₹312.35 crore, while employee-benefit expense was ₹73.43 crore. These are group-level figures cited in the available updates and should not be treated as measures of the standalone ₹222.49 crore sales result.

What financial background is relevant for investors?

Camlin Fine Sciences’ full-year 2026 update reported revenue of ₹1,720 crore, up 5.8% from FY2025, alongside a net loss of ₹27.45 crore. The update said this compared with a profit in FY2025 and reported a loss per share of ₹1.45, against earnings per share of ₹4.86 in the previous financial year.

A separate second-quarter 2026 earnings update reported revenue of ₹464 crore, up 9.8% year on year, and a net loss of ₹5.44 crore. The loss per share was ₹0.29, an improvement from a loss per share of ₹5.98 in the corresponding quarter of the prior year. These figures show that revenue growth and profit outcomes did not necessarily move together in the periods covered by the supplied information.

The company’s annual operating cash flow was reported at ₹82.07 crore in FY2026, compared with ₹23 crore in FY2025. This improvement in operating cash generation is a separate measure from accounting profit or loss and must be assessed alongside the company’s expenses, working-capital requirements, and financing decisions.

What will Camlin Fine Sciences consider on November 3, 2026?

Camlin Fine Sciences has scheduled a board meeting on November 3, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company also announced an investor call on the same date to discuss unaudited Q2 and H1 FY27 results with analysts and investors.

The board is also expected to consider a proposal to raise funds through a rights issue of equity shares. The supplied announcement does not specify the proposed issue size, price, record date, entitlement ratio, or intended use of proceeds. Those details remain material for shareholders because a rights issue can affect the company’s equity base and shareholding structure.

The company said its trading window closed on October 1, 2026 and will remain closed until 48 hours after the release of the unaudited financial results. The closure was described as being in line with SEBI insider-trading norms. Separately, independent director Pradip Kanakia ceased to be an independent director after his term ended on October 18, 2026.

How does the June sales update affect investors and operations?

The 16.22% growth in standalone sales provides a positive revenue data point for Camlin Fine Sciences’ parent-company operations. However, the group-level data supplied for June 2026 shows that higher revenue did not prevent a decline in operating profit and operating margin compared with March 2026. Investors therefore have limited basis to infer earnings performance from the standalone sales number alone.

The November 3 results and investor call are the next disclosed events that may provide a more current view of sales, expenses, margins, profit or loss, and cash flow for the September quarter and first half. The proposed rights issue is also relevant because the board’s decision and any subsequent terms could influence the company’s capital structure.

For the specialty chemicals industry, input costs and operating expenses can affect margins even when sales rise. The disclosed June figures reflect this distinction: consolidated sales were reported at ₹520 crore, while operating profit in the quarterly table was ₹9 crore and the operating margin was 1.8%.

Conclusion

Camlin Fine Sciences’ standalone net sales of ₹222.49 crore for June 2026, up 16.22% year on year, point to revenue growth at the parent-company level. But the available consolidated data also shows lower operating profit and margin in June than in March, while FY2026 ended with a reported net loss despite higher revenue.

The next disclosed milestone is the November 3, 2026 board meeting, when Camlin Fine Sciences is due to consider its September-quarter and half-year results as well as a possible equity rights issue. Investors will watch for the financial results and, if approved, the terms and purpose of any proposed fund raising.